The estimated Net Worth of Gregory A Md Demopulos is at least $5.28 million dollars as of 17 November 2023. Gregory Demopulos owns over 15,000 units of Omeros stock worth over $456,118 and over the last 15 years he sold OMER stock worth over $0. In addition, he makes $4,825,130 as Chairman of the Board, President et Chief Executive Officer at Omeros.
Sign up
Gregory Demopulos OMER stock SEC Form 4 insiders trading
Gregory has made over 16 trades of the Omeros stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of OMER stock worth $25,200 on 17 November 2023.
The largest trade he's ever made was exercising 487,283 units of Omeros stock on 30 November 2016 worth over $477,537. On average, Gregory trades about 45,424 units every 136 days since 2010. As of 17 November 2023 he still owns at least 123,945 units of Omeros stock.
You can see the complete history of Gregory Demopulos stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gregory Demopulos biography
Dr. Gregory A. Demopulos M.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. He founded our company and has served as our president, chief executive officer and chairman of the board of directors since June 1994. He also served as our chief financial officer and treasurer from January 2009 to October 2013 in an interim capacity and as our chief medical officer from June 1994 to March 2010. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University. Dr. Demopulos currently serves on the board of trustees of the Smead Funds Trust, an open-end mutual fund company registered under the Investment Company Act of 1940. Dr. Demopulos received his M.D. from Stanford University School of Medicine and his B.S. from Stanford University. Our nominating and governance committee has concluded that Dr. Demopulos should continue to serve on the board of directors based on his position and experience as our chief executive officer and his medical and scientific expertise, experience with clinical development and design and knowledge of our operations and development programs. Dr. Demopulos is the brother of Peter A. Demopulos, M.D., a member of our board of directors.
What is the salary of Gregory Demopulos?
As the Chairman of the Board, President et Chief Executive Officer of Omeros, the total compensation of Gregory Demopulos at Omeros is $4,825,130. There are no executives at Omeros getting paid more.
How old is Gregory Demopulos?
Gregory Demopulos is 61, he's been the Chairman of the Board, President et Chief Executive Officer of Omeros since 2013. There are 15 older and 14 younger executives at Omeros. The oldest executive at Omeros Corporation is Ray Aspiri, 83, who is the Independent Director.
What's Gregory Demopulos's mailing address?
Gregory's mailing address filed with the SEC is 201 ELLIOTT AVENUE WEST, , SEATTLE, WA, 98119.
Insiders trading at Omeros
Over the last 15 years, insiders at Omeros have traded over $719,810 worth of Omeros stock and bought 141,095 units worth $829,835 . The most active insiders traders include Gregory A Md Demopulos, Marcia S. Kelbon et Daniel K Spiegelman. On average, Omeros executives and independent directors trade stock every 53 days with the average trade being worth of $97,792. The most recent stock trade was executed by Gregory A Md Demopulos on 17 November 2023, trading 15,000 units of OMER stock currently worth $25,200.
What does Omeros do?
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
What does Omeros's logo look like?
Complete history of Gregory Demopulos stock trades at Omeros
Omeros executives and stock owners
Omeros executives and other stock owners filed with the SEC include:
-
Gregory Demopulos,
Chairman of the Board, President, Chief Executive Officer -
Dr. Gregory A. Demopulos,
Co-Founder, Chairman, CEO & Pres -
Dr. Gregory A. Demopulos M.D.,
Co-Founder, Chairman, CEO & Pres -
Michael Jacobsen,
Chief Accounting Officer, Vice President - Finance, Treasurer -
Peter Cancelmo,
Vice President, General Counsel, Secretary -
Michael A. Jacobsen,
Chief Accounting Officer, VP of Fin. & Treasurer -
Peter B. Cancelmo J.D.,
VP, Gen. Counsel & Corp. Sec. -
Thomas Bumol,
Independent Director -
Thomas Cable,
Lead Independent Director -
Ray Aspiri,
Independent Director -
Arnold Hanish,
Independent Director -
Leroy Hood,
Independent Director -
Rajiv Shah,
Independent Director -
Peter Demopulos,
Director -
Kurt Zumwalt,
Independent Director -
Timothy Duffy,
Vice President - Business Development -
J. Steven Whitaker,
Vice President, Chief Medical Officer -
Tina Quinton,
Vice President - Patents -
Catherine Melfi,
Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory Officer -
Bruce Meiklejohn,
Vice President - Chemistry, Manufacturing and Controls -
Daniel Kirby,
Vice President, Chief Commercial Officer -
Christopher Bral,
Vice President - Nonclinical Development -
George Gaitanaris,
Chief Scientific Officer, Vice President - Science -
Dr. J. Steven Whitaker J.D., M.D.,
VP of Clinical Devel. & Chief Medical Officer -
Dr. Pamela Pierce Palmer M.D., Ph.D.,
Co-Founder -
Nadia Dac,
Chief Commercial Officer -
Dr. Catherine A. Melfi,
Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems -
Dr. J. Steven Whitaker,
VP of Clinical Devel. & Chief Medical Officer -
Peter W. Williams,
VP of HR -
Dr. George A. Gaitanaris M.D., Ph.D.,
Chief Scientific Officer & VP of Science -
Dr. Pamela Pierce Palmer,
Co-Founder -
Marcia S. Kelbon,
VP Patent and General Counsel -
Diana T. Perkinson,
Director -
Daniel K Spiegelman,
Director -
Jean Philippe Tripet,
Director